Eco Animal Health Group PLC Result of AGM

RNS Number : 0770G

Eco Animal Health Group PLC

27 September 2024

 

27 September 2024

 

 

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Result of Annual General Meeting

  

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that at its Annual General Meeting held yesterday all resolutions proposed to the meeting were duly passed.

Votes received in relation to each resolution were as follows:

Resolution	For	%	Discretionary	%	Against	%
01	41,070,268	100.00	Nil	0.00	Nil	0.000
02	36,456,852	88.768	Nil	0.00	4,613,165	11.232
03	40,961,390	99.735	Nil	0.00	108,878	0.265
04	34,395,129	84.081	Nil	0.00	6,511,866*	15.919
05	41,070,404	99.999	Nil	0.00	541	0.001
06	40,976,766	99.771	Nil	0.00	94,179	0.229
07	40,945,821	99.709	784	0.002	118,663	0.289
08	40,957,821	99.726	784	0.002	111,663	0.272
09	41,046,763	99.941	7,500	0.018	16,682	0.041

 

* Note: The Board has been informed that a shareholder holding a block of 1,902,729 votes incorrectly lodged a proxy in respect of these shares against resolution 4.  This shareholder acknowledged that  the intent had been to vote these shares in favour of resolution 4.

-Ends-

For further information please contact:

 

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) 020 8447 8899   Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher 020 7496 3000 Investec (Joint Broker) Gary Clarence Lydia Zychowska 020 7597 5970     Equity Development Hannah Crowe Matt Evans 020 7065 2692 ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson 020 3709 5700 [e-mail]

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

 Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

 Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RAGSEUFDWELSEFU